定位放射線治療を受けている前立腺癌患者における SpaceOAR Vue システムの有効性 (SABRE)
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study is designed to evaluate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in participants undergoing Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Cork、アイルランド、T12 DV56
- Bon Secours Radiotherapy Cork
-
-
-
-
Florida
-
Fort Myers、Florida、アメリカ、33908
- GenesisCare USA
-
Tampa、Florida、アメリカ、33609
- Florida Urology Partners, LLC
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- Kansas University Medical Center
-
-
Michigan
-
Troy、Michigan、アメリカ、48098
- GenesisCare USA
-
-
New Jersey
-
Bloomfield、New Jersey、アメリカ、07003
- New Jersey Urology, a Summit Health Company
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Myrtle Beach、South Carolina、アメリカ、29572
- Dr. John Sylvester
-
-
-
-
-
Belfast、イギリス、BT9 7AB
- Belfast City Hospital
-
Bristol、イギリス、BS2 8ED
- Bristol Haematology and Oncology Centre
-
London、イギリス、SW3 6JJ
- Royal Marsden Hospital
-
Norwich、イギリス、NR4 7UY
- Norfolk and Norwich University Hospital NHS Trust
-
Plymouth、イギリス、PL6 8DH
- Derriford General Hospital
-
-
Surrey
-
Guildford、Surrey、イギリス、GU27XX
- Royal Surrey County Hospital NHS Foundation Trust
-
-
Wales
-
Cardiff、Wales、イギリス、CF14 2TL
- Velindre Cancer Centre
-
-
-
-
-
Parma、イタリア、43126
- Azienda Ospedaliero Universitaria di Parma
-
Rome、イタリア
- Policlinico Universitario Agostino Gemelli
-
Verona、イタリア、37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
-
-
-
New South Wales
-
Waratah、New South Wales、オーストラリア、2298
- Calvary Mater Newcastle
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア、4102
- Princess Alexandra Hospital - ROPAIR
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア、6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Basel、スイス、CH-4031
- University Hospital Basel
-
Bern、スイス、3010
- Inselspital - University Hospital Bern
-
-
-
-
-
Barakaldo、スペイン、48903
- Hospital Universitario Cruces
-
Madrid、スペイン、28002
- GenesisCare, Hospital San Francisco de Asis
-
Madrid、スペイン
- Hospital Universitario Ramón y Cajal
-
-
-
-
-
Bonn、ドイツ、D-53129
- MEDICLIN Robert Janker Klinik
-
Nuremberg、ドイツ、90419
- Klinikum Nurnberg Nord
-
-
-
-
-
Levallois-Perret、フランス、92300
- Institut de Radiothérapie & Radiochirurgie HARTMANN
-
-
Cedex
-
Villejuif、Cedex、フランス、94805
- Institut Gustave Roussy
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years old.
- Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
- Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
- Clinical Stage T2b - T2c (AJCC 6th edition) tumor
- Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
Exclusion Criteria:
- Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
- Clinical stage T3 or T4 (AJCC 6th edition) tumor
- Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
- Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
- Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
- History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
- History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
- History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
- History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
- Bleeding hemorrhoids requiring medical intervention within the prior three months.
- Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
- Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
- Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
- If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
- Unable to comply with the study requirements or follow-up schedule.
- Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
- Known iodine sensitivity or allergy
- Known polyethylene glycol (PEG) sensitivity or allergy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:No-Spacer Control
Subjects will receive radiotherapy without the use of the SpaceOAR Vue. |
|
|
実験的:SpaceOAR Vue
Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel. |
The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Late Gastrointestinal (GI) Toxicity
時間枠:3 to 24 months post-SBRT initiation
|
Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation |
3 to 24 months post-SBRT initiation
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
EPIC-26 bowel score
時間枠:24 months post-SBRT initiation
|
Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation. |
24 months post-SBRT initiation
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Suneil Jain, MB, BCh, PhD、Queen's University, Belfast
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- U0702
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。